pSivida updates clinical programs

pSivida (NASDAQ:PSDV; ASX:PVA) in its first quarter (ended September 30) report updated its three clinical-stage product candidates for the treatment of back-of-the-eye diseases. The most advanced is Iluvien for diabetic macular edema (DME) being developed by licensee, Alimera Sciences, which has resubmitted a New Drug Application and is awaiting a response from the FDA. The [...]

pSivida insert in new trial for posterior uveitis

pSivida (NASDAQ:PSDV; ASX:PVA) has opened an investigational new drug application for a Phase 1/2 clinical trial to study an injectable, sustained release insert delivering the corticosteroid fluocinolone acetonide (FAc) for the treatment of uveitis affecting the posterior segment of the eye, or posterior uveitis. An insert of the same design is being developed for the [...]

pSivida takes us on a fantastic voyage to the back of the eye

After developing several miniaturized, injectable drug delivery systems for the treatment of niche ocular diseases, pSivida (NASDAQ:PSDV; ASX:PVA) is now at the precipice of several blockbuster indications, including diabetic macular edema (DME), age-related macular degeneration (AMD) and glaucoma, with its next-generation Durasert device. And in early development is a new generation Tethadur platform that relies [...]